Pfizer’s Abrocitinib Quick Off The Mark In Atopic Dermatitis

Top-Line Results From Third Phase III Study

Pfizer’s next-generation JAK1 inhibitor, abrocitinib, continues to show beneficial effects in atopic dermatitis (eczema), in the JADE COMPARE study, comparable to the positive control dupilumab and, in the case of itch, with a faster onset at the higher dose.  

Starting_Blocks
• Source: Shutterstock

Pfizer Inc.’s next-generation oral JAK1 inhibitor, abrocitinib, is likely to be a strong competitor to Sanofi/Regeneron Pharmaceuticals Inc.’s Dupixent (dupilumab) for treating atopic dermatitis, judging by top-line results from a third Phase III study which showed a higher dose of abrocitinb was significantly superior to the interleukin-4/IL-13 inhibitor, dupilumab, in reducing itch after the first two weeks of therapy.

Having a quicker effect on symptoms could be an important differentiator for abrocitinib in its likely marketing battle with the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category